• 1
    Holland S, Silberstein SD, Freitag F, Dodick DW, Argoff C. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults. Neurology. 2012;78:1346-1353.
  • 2
    Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C. Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults. Neurology. 2012;78:1337-1345.
  • 3
    D'Amico D, Solari A, Usai S, et al. Improvement in quality of life and activity limitations in migraine patients after prophylaxis. A prospective longitudinal multicentre study. Cephalalgia. 2006;26:691-696.
  • 4
    Brown JS, Papadopoulos G, Neumann PJ, Friedman M, Miller JD, Menzin J. Cost-effectiveness of topiramate in migraine prevention: Results from a pharmacoeconomic model of topiramate treatment. Headache. 2005;45:1012-1022.
  • 5
    Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68:343-349.
  • 6
    Diamond S, Bigal ME, Silberstein S, Loder E, Reed M, Lipton RB. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: Results from the American Migraine Prevalence and Prevention study. Headache. 2007;47:355-363.
  • 7
    Oxman AD, Glasziou P, Williams JW Jr. What should clinicians do when faced with conflicting recommendations? BMJ. 2008;337:a2530.
  • 8
    Rouse C. Patient and practitioner noncompliance: Rationing, therapeutic uncertainty, and the missing conversation. Anthropol Med. 2010;17:187-200.
  • 9
    Mottur-Pilson C, Snow V, Bartlett K. Physician explanations for failing to comply with “best practices. Eff Clin Pract. 2001;4:207-213.
  • 10
    Burda BU, Norris SL, Holmer HK, Ogden LA, Smith ME. Quality varies across clinical practice guidelines for mammography screening in women aged 40-49 years as assessed by AGREE and AMSTAR instruments. J Clin Epidemiol. 2011;64:968-976.
  • 11
    Cates JR, Young DN, Bowerman DS, Porter RC. An independent AGREE evaluation of the Occupational Medicine Practice Guidelines. Spine J. 2006;6:72-77.
  • 12
    Nagy E, Watine J, Bunting PS, et al. Do guidelines for the diagnosis and monitoring of diabetes mellitus fulfill the criteria of evidence-based guideline development? Clin Chem. 2008;54:1872-1882.
  • 13
    Alonso-Coello P, Irfan A, Sola I, et al. The quality of clinical practice guidelines over the last two decades: A systematic review of guideline appraisal studies. Qual Saf Health Care. 2010;19:e58.
  • 14
    Brouwers MC, Kho ME, Browman GP, et al. AGREE II: Advancing guideline development, reporting and evaluation in health care. J Clin Epidemiol. 2010;63:1308-1311.
  • 15
    Silberstein SD. Practice parameter: Evidence-based guidelines for migraine headache (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;55:754-762.
  • 16
    Vedula SS, Bero L, Scherer RW, Dickersin K. Outcome reporting in industry-sponsored trials of gabapentin for off-label use. N Engl J Med. 2009;361:1963-1971.
  • 17
    Demarin V, Vukovic V, Lovrencic-Huzjan A, et al. Evidence based guidelines for the treatment of primary headaches. Acta Med Croatica. 2008;62:99-136.
  • 18
    Treatment Guideline Subcommittee of the Taiwan Headache Society. Treatment guidelines for preventive treatment of migraine. Acta Neurol Taiwan. 2008;17:132-148.
  • 19
    Ravishankar K, Chakravarty A, Chowdhury D, Shukla R, Singh S. Guidelines on the diagnosis and the current management of headache and related disorders. Ann Indian Acad Neurol. 2011;14(Suppl. 1):S40-S59.
  • 20
    Canadian Headache Society Prophylactic Guidelines Development Group. Canadian headache society guideline for migraine prophylaxis. Can J Neurol Sci. 2012;39(2 Suppl. 2):1-62.
  • 21
    Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine – revised report of an EFNS task force. Eur J Neurol. 2009;16:968-981.
  • 22
    Tfelt-Hansen P, Bjarnason NH, Dahlof C, et al. Evaluation and registration of adverse events in clinical drug trials in migraine. Cephalalgia. 2008;28:683-688.
  • 23
    Tfelt-Hansen P, Pascual J, Ramadan N, et al. Guidelines for controlled trials of drugs in migraine: Third edition. A guide for investigators. Cephalalgia. 2012;32:6-38.
  • 24
    Ioannidis JP. Adverse events in randomized trials: Neglected, restricted, distorted, and silenced. Arch Intern Med. 2009;169:1737-1739.
  • 25
    McCrory D. Report on gabapentin (Neurontin®) for migraine prophylaxis: Evaluation of efficacy, effectiveness and marketing. Expert consultant's report. Available at: (accessed April 12, 2012).
  • 26
    Loder E. Menstrual migraine: Timing is everything. Neurology. 2004;63:202-203.
  • 27
    Chan AW. Out of sight but not out of mind: How to search for unpublished clinical trial evidence. BMJ. 2012;344:d8013.
  • 28
    Wieseler B, Kerekes MF, Vervoelgyi V, McGauran N, Kaiser T. Impact of document type on reporting quality of clinical drug trials: A comparison of registry reports, clinical study reports, and journal publications. BMJ. 2012;344:d8141.
  • 29
    Wieland LS, Robinson KA, Dickersin K. Understanding why evidence from randomised clinical trials may not be retrieved from Medline: Comparison of indexed and non-indexed records. BMJ. 2012;344:d7501.
  • 30
    Lehman R, Loder E. Missing clinical trial data. BMJ. 2012;344:d8158.
  • 31
    Tfelt-Hansen P. Subcutaneous sumatriptan: Results of a peculiar, unpublished, comparative, double-blind, randomised, and controlled trial. J Headache Pain. 2011;12:269-270.
  • 32
    Tfelt-Hansen PC. Published and not fully published double-blind, randomised, controlled trials with oral naratriptan in the treatment of migraine: A review based on the GSK Trial Register. J Headache Pain. 2011;12:399-403.
  • 33
    Tfelt-Hansen PC. Unpublished clinical trials with sumatriptan. Lancet. 2009;374:1501-1502.
  • 34
    Hart B, Lundh A, Bero L. Effect of reporting bias on meta-analyses of drug trials: Reanalysis of meta-analyses. BMJ. 2012;344:d7202.